# Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

> **NCT06364826** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Sintilimab, bevacizumab, gemcitabine
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT06364826
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-22
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364826, "Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06364826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*